Stryker Corporation

Stryker Corporation

Stryker Corporation (SYK) is a global medical‑technology company best known for orthopaedics, surgical equipment, neurotechnology and patient-handling systems. Investors should know it sells high-margin implants, powered surgical tools and capital equipment to hospitals and clinics, giving it exposure to both recurring consumable sales and larger, cyclical procedure volumes. Growth drivers include an ageing population, innovation in implants and minimally invasive procedures, geographic expansion and selective acquisitions. Key considerations are sensitivity to elective-surgery cycles, hospital capital spending and regulatory approvals; reimbursement policies and competition from other device makers can also affect results. Stryker has a track record of reinvesting in R&D, pursuing M&A and returning cash to shareholders, but margins and growth rates can vary over time. This is general, educational information only β€” not personal investment advice. Values can rise and fall and past performance is not a reliable guide. Suitability depends on your circumstances; consider seeking regulated financial advice before investing.

Why It's Moving

Stryker Corporation

Stryker's $25 Billion Momentum Derailed by Iranian-Linked Cyberattack Wiping 200,000+ Systems

On March 11, 2026, Stryker Corporation suffered a destructive cyberattack attributed to an Iranian-linked hacking group called Handala that paralyzed its global Microsoft environment and wiped over 200,000 devices. The attack disrupted order processing, manufacturing, and shipping operations across 56,000 employees in 61 countries, sending shares down 9% as investors assessed the financial and operational fallout.
Sentiment:
🐻Bearish
  • The wiper attackβ€”which destroyed data rather than encrypting it for ransomβ€”is more damaging than typical ransomware because recovery is more complex and permanent data loss complicates systems restoration
  • Manufacturing and shipping disruptions directly threaten near-term revenue recognition and could force Stryker to revise guidance if operations don't normalize by late March, particularly after launching its SmartHospital Platform just days before the attack
  • Stryker is running additional shifts and manual ordering processes to manage backlog while systems come back online, but the full timeline for restoration remains unclear as of March 13

When is the next earnings date for Stryker Corporation (SYK)?

Stryker Corporation's next earnings announcement is estimated to occur between April 28 and May 7, 2026, covering the first quarter of 2026, though the company has not yet officially confirmed the specific date. Based on historical patterns, the company typically releases earnings in late April or early May. Investors should monitor Stryker's investor relations website for official confirmation of the exact announcement date and webcast details.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Stryker's stock, expecting it to rise significantly in value.

Above Average

Financial Health

Stryker Corporation is showing strong profits and cash flow, indicating solid business performance.

Below Average

Dividend

Stryker's dividend yield of 0.92% is low, making it less appealing for dividend-focused investors. If you invested $1000 you would be paid $9.20 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring SYK

Healthcare Titans: Brazil Growth vs Currency Volatility

Healthcare Titans: Brazil Growth vs Currency Volatility

Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.

Published: October 14, 2025

Explore Basket
Healthcare Innovation: MedTech Giants Portfolio 2025

Healthcare Innovation: MedTech Giants Portfolio 2025

Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.

Published: September 22, 2025

Explore Basket

Why You’ll Want to Watch This Stock

πŸ“ˆ

Elective Surgery Exposure

Stryker benefits from demand for joint replacements and minimally invasive procedures, though revenues can move with surgical volumes and economic cycles.

⚑

Innovation and M&A

Regular new-product launches and selective acquisitions can extend market share, but integration and regulatory approval carry execution risk.

🌍

Global Footprint

Diversified geographic presence helps growth and resilience, though it brings exposure to local reimbursement policies and currency fluctuations.

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

A

Agilent Technologies Inc.

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

ALGN

Align Technology Inc.

Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.

Frequently asked questions